↓ Skip to main content

Dove Medical Press

Article Metrics

Embed badge What is this page?

Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy

Overview of attention for article published in International Journal of Nanomedicine, June 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (54th percentile)
  • Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
40 Mendeley

What is this page?

Summary Twitter Dimensions citations
Title
Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy
Published in
International Journal of Nanomedicine, June 2015
DOI 10.2147/ijn.s83211
Pubmed ID
26089667
Authors

Xu Lei-Ming, Chun-Ying Qu, Min Zhou, Ying-wei Chen, Mei-mei Chen, Feng Feng Shen

Abstract

The first-line chemotherapy treatment protocol for gastric cancer is combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP). The aim of this study was to engineer prodrug-based nanostructured lipid carriers (NLC) platform for codelivery of 5-FU and CDDP to enhance therapy and decrease toxicity. First, 5-FU-stearic acid lipid conjugate was synthesized by two steps. Second, 5-FU-stearic acid prodrug and CDDP were loaded in NLC. Finally, hyaluronic acid (HA) was coated onto NLC surface. Average size, zeta potential, and drug loading capacity of NLC were evaluated. Human gastric cancer cell line BGC823 (BGC823 cells) was used for the testing of in vitro cytotoxicity assays. In vivo antitumor activity of NLC was evaluated in mice bearing BGC823 cells model. HA-coated 5-FU-stearic acid prodrug and CDDP-loaded NLC (HA-FU/C-NLC) showed a synergistic effect in combination therapy and displayed the greatest antitumor activity than all of the free drugs or uncoated NLC in vitro and in vivo. This work reveals that HA-coated NLC could be used as a novel carrier to code-liver 5-FU and CDDP for gastric cancer therapy. HA-FU/C-NLC could be a promising targeted and combinational therapy in nanomedicine.

View on publisher site

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 25%
Student > Master 7 18%
Student > Postgraduate 4 10%
Student > Bachelor 3 8%
Other 2 5%
Other 6 15%
Unknown 8 20%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 11 28%
Agricultural and Biological Sciences 4 10%
Chemistry 4 10%
Biochemistry, Genetics and Molecular Biology 4 10%
Medicine and Dentistry 2 5%
Other 6 15%
Unknown 9 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 June 2015.
All research outputs
#2,319,497
of 5,218,660 outputs
Outputs from International Journal of Nanomedicine
#311
of 1,380 outputs
Outputs of similar age
#78,173
of 177,515 outputs
Outputs of similar age from International Journal of Nanomedicine
#22
of 95 outputs
Altmetric has tracked 5,218,660 research outputs across all sources so far. This one has received more attention than most of these and is in the 54th percentile.
So far Altmetric has tracked 1,380 research outputs from this source. They receive a mean Attention Score of 1.7. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 177,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.

This page is hosted by Altmetric on behalf of Dove Medical Press.